TECHNICAL FIELD
The present disclosure generally relates to cutaneous neurostimulator systems, devices and methods of using the same and more particularly relates to cutaneous neurostimulator systems, devices and methods for treating or promoting recovery from neurological disorders or conditions,
TECHNICAL FIELD
The present disclosure generally relates to cutaneous neurostimulator systems, devices and methods of using the same and more particularly relates to cutaneous neurostimulator systems, devices and methods for treating or promoting recovery from neurological disorders or conditions,
This application is also related to the following copending applications: U.S. application Ser. No. 12/898,685, entitled "Extracranial Implantable Devices, Systems and Methods for Treatment of Neuropsychiatric Disorders," filed on even date herewith with U.S. application Ser. No. 12/898,686,
FIELD OF THE INVENTION
The present invention relates to a pharmaceutical composition for treatment and/or prevention of a disease due to constriction or vasodilation of blood vessels comprising EDG(Endothelial differentiation gene)-5 modulator which is useful as a drug, and relates to novel EDG-5
BACKGROUND OF THE INVENTION
Mammalian Endogenous Cannabinoid System
The various elements of the mammalian endogenous cannabinoid system (ECS) constitute a variety of pharmacological targets for the broad group of compounds generally termed as cannabinoids. Included among these elements are two types
BACKGROUND OF THE INVENTION
Mammalian Endogenous Cannabinoid System
The various elements of the mammalian endogenous cannabinoid system (ECS) constitute a variety of pharmacological targets for the broad group of compounds generally termed as cannabinoids. Included among these elements are two types
BACKGROUND OF THE INVENTION
Mammalian Endogenous Cannabinoid System
The various elements of the mammalian endogenous cannabinoid system (ECS) constitute a variety of pharmacological targets for the broad group of compounds generally termed as cannabinoids. Included among these elements are two types
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to aminoalkyl substituted 5,6,7,8-tetrahydro-9H-pyridino[2,3-b]indole and 5,6,7,8-tetrahydro-9H-pyrimidino[4,5-b]indole derivatives, pharmaceutical compositions containing such compounds and their use in treating
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to aminoalkyl substituted 5,6,7,8-tetrahydro-9H-pyridino[2,3-b]indole and 5,6,7,8-tetrahydro-9H-pyrimidino[4,5-b]indole derivatives, pharmaceutical compositions containing such compounds and their use in treating
FIELD OF THE INVENTION
The invention presented herein is directed to novel imidazopyrimidinyl and imidazopyridinyl derivatives, and to their use as CRF antagonists in the treatment of a variety of neurological and psychiatric disorders.
BACKGROUND OF THE INVENTION
Corticotropin releasing factor
The most complete medicinal herbs database backed by science
Works in 55 languages
Herbal cures backed by science
Herbs recognition by image
Interactive GPS map - tag herbs on location (coming soon)
Read scientific publications related to your search
Search medicinal herbs by their effects
Organize your interests and stay up do date with the news research, clinical trials and patents
Type a symptom or a disease and read about herbs that might help, type a herb and see diseases and symptoms it is used against. *All information is based on published scientific research